AndhraNews.net
Home » Features » Health » Ovarian Cancer

Ovarian Cancer


About Ovarian Cancer

Ovarian Cancer in News

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Business Wire IndiaMerck and Pfizer announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer

Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Business Wire IndiaMerck and Pfizer announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates

Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Business Wire IndiaMerck and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen

Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Business Wire IndiaNot intended for UK-based media

Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article

Avant Diagnostics, Inc. Announces Launch of New Corporate Website
SCOTTSDALE, AZ--(Marketwired - December 15, 2015) - Avant Diagnostics, Inc. (OTCQB: AVDX), "Avant", unveiled its new website on December 12, 2015. The site, avantdiagnostics.com, incorporates numerous features to make browsing a more streamlined and informative experience for the Company's current and potential customers and investors

Soricimed Completes Phase 1 Trial of SOR-C13 in Advanced Solid Tumour Cancers
Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, today announced that it has reached its target enrollment and treatment duration in its Phase 1 trial. The Phase 1 is designed to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other treatments

Cellceutix First Annual Shareholder Meeting December 15, 2015
BEVERLY, MA--(Marketwired - December 14, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reminds shareholders that tomorrow is the first annual Cellceutix shareholder meeting

Inspire Launches Redesigned Online Health Community to Improve Patient and Caregiver Experience
PRINCETON, NJ--(Marketwired - December 07, 2015) - Inspire, the largest social network for patients and caregivers, has released an upgraded design that enables patients to better engage with and navigate the site, and meets the needs of the growing group of mobile healthcare consumers.

FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
BEVERLY, MA--(Marketwired - November 25, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S

Dr. Robert C. Young Joins NCCN Leadership Team
FORT WASHINGTON, PA--(Marketwired - November 16, 2015) - The National Comprehensive Cancer Network® (NCCN®) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program (ORP).

Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer

Ponce Health Sciences University Attracts Top-Tier Medical Researchers to Address Growing Health Disparities Among Hispanics
The Ponce Health Sciences University (PHSU), a fully accredited U.S. medical school, has announced the hiring of two leading researchers to address growing disparities among Hispanics and other minorities in the United States. Dr. Harold Saavedra, cancer biologist from Emory University, and Dr

Immunovaccine Announces Financial Results for Quarter Ended September 30, 2015
Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX: IMV) (OTCQX: IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the third quarter ended September 30, 2015.

Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics

Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015
BEVERLY, MA--(Marketwired - November 10, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2015 with the Securities and Exchange Commission

BioCancell Advances Intellectual Property Portfolio in the United States
BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer-related diseases, today announced that the U.S. Patent and Trademark Office has approved a patent for BioCancell's second-generation drug, BC-821

Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
Basilea Pharmaceutica AG /Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 04, 2015) - BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") is pleased to announce that the U.S. Food and Drug Administration (FDA) has given final clearance for the Company's Investigational New Drug (IND) application to initiate a Phase I/IIa clinical trial of BriaVax™

MD Anderson's Moon Shots Mission Grows to Confront Six More Cancer Types
HOUSTON, TX--(Marketwired - October 30, 2015) - MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.

Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer

Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company") announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms ("SNPs") improves the predictive accuracy of four commonly used breast cancer risk assessment models

Women's Executive Network Reveals 2014 Canada's Most Powerful Women: Top 100 Award Winners
Who are some of Canada's boldest female leaders who will stop at nothing to push boundaries within their careers and organizations?

Published Review and Analyst Report Boost TapImmune Shares
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.

CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

Bryan Zuriff Attends 4th Biennial Stand Up To Cancer Benefit
Celebrities and television viewers across the United States and Canada joined forces to raise $109 million during the fourth Biennial Stand Up To Cancer telethon. The September 5th event packed the house at Hollywood's Dolby Theatre where among the television and movie industry executives in attendance was Bryan Zuriff, executive producer of Showtime's hit drama series "Ray Donovan

Producer Bryan Zuriff to Attend Twentieth Anniversary OCRF Legends Gala
Celebrating twenty years of cancer research, the Ovarian Cancer Research Fund (OCRF) will hold its Twentieth Anniversary Legends Gala in New York City this year, at the Pierre Hotel on Fifth Avenue. The OCRF, founded in 1994, is the largest and oldest ovarian research charity and is third in overall ovarian cancer research. Hosted by Harry Connick Jr

immixGroup Foundation Tenth Annual Charity Golf Tournament Raises $125,000 for Cancer Research
MCLEAN, VA--(Marketwired - October 03, 2014) - The immixGroup Foundation announced today it has raised $125,000 to support cancer research, education, and patient care at Johns Hopkins. The foundation is a non-profit 501(c)(3) organization affiliated with immixGroup, Inc. immixGroup helps technology companies do business with the government.

Cellceutix Provides Update to Shareholders
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications today has provided an update to its shareholders.

Rosetta Genomics Reports Financial Results for the First Half of 2014
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today reported financial results for the six months ended June 30, 2014.

Witty Cancer Survivor Jennie McGihon to Headline September 18 "Teal To-Do" at Denver Athletic Club
Jennie McGihon, who at 32-years-young wrote about her treatment for ovarian and uterine cancers in the witty, you-picked-the-wrong-girl-to-mess-with blog, "Are You There Cancer? It's Me, Jennie," will be the guest speaker at the inaugural "Teal To-Do" Gala Thursday, September 18 in the Grand Ballroom of the Denver Athletic Club

BRCA Gene Testing-Based Breast Cancer and Ovarian Cancer Keynote Speaker, Advocate, Advisor and 'Previvor' Launches 'BRCA Believer' Brand Inspired by Personal Experience
SAN DIEGO, CA--(Marketwired - July 22, 2014) - BRCA gene testing-based breast cancer and ovarian cancer keynote speaker, advocate, advisor and "previvor," Merilee Kern, today announced the launch of the "BRCA Believer" shirt and merchandise line (www.BRCABeliever

Global Drug Delivery in Cancer Report 2014-Technologies, Markets and Companies
Research and Markets (http://www.researchandmarkets.com/research/hcwjdn/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that a research article titled "A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer" was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. Dr. Paul Mitchell is the lead author.

Prima BioMed to Present at 2014 WAGO Annual Meeting

CVAC Demonstrates Positive Trend in Overall Survival in Second Remission Ovarian Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)

Prima Biomed to Host Conference Call to Discuss Abstract Presented at ASCO on New Interim Overall Survival and Final Progression Free Survival Data for the Company's CAN-003 Trial
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Company will host a conference call and webcast covering Dr. Heidi Gray's oral presentation at the American Society of Clinical Oncology ("ASCO") to be given on May 31, 2014 in Chicago, IL. The call and webcast will include discussions from both Dr. Gray and Dr. Monk on data presented at ASCO.

Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
Takeda Pharmaceutical Company Limited (TSE:4502) has announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide

Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Merck (MRK GY) (FWB:MRK) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

Pathway Genomics Launches BRCA1/2 Genetic Test with One for One Program
Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer

Goldman Small Cap Research Initiates Research Coverage of Arrayit Corporation

Stellar Biotechnologies Announces Collaboration With Amaran Biotechnology, Inc.
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it has entered into a collaboration agreement with Amaran Biotechnology, Inc

Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants
The Ovarian Cancer Symptom Awareness Organization (OCSA) continues to unleash innovative ways to educate women and their families about the silent symptoms of ovarian cancer and the importance of early detection

Genetic Technologies Announces Publication Highlighting Cost-Effectiveness of BREVAGen(TM) in Cancer Prevention Research
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced its flagship genetic breast cancer risk prediction test, BREVAGen™, is featured in the online issue of Cancer Prevention Research Vol 6 (12): pp 1328 - 36 dated December 5, 2013. The publication profiles the cost-effectiveness of the BREVAGen™ test versus direct MRI screening for breast cancer risk

Expert Panel to Discuss Prima BioMed's CVac Clinical Trial Data in Ovarian Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that its recently reported CVac clinical trial results will be the focus of an upcoming expert panel discussion entitled "Ovarian Cancer: Next Generation Immunotherapies" to be held via conference call on Thursday, December 12, 2013 at 8:00am Sydney local time

Glycotope Doses First Patients in Phase IIb Study with PankoMab-GEX(TM) for the Maintenance Therapy of Ovarian Carcinoma
Glycotope GmbH /Glycotope Doses First Patients in Phase IIb Study with PankoMab-GEX(TM) for the Maintenance Therapy of Ovarian Carcinoma . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Jo Schantz Named Executive Director of Colorado Ovarian Cancer Alliance
Jo Schantz, MNM, of Golden, Colo., has been selected as the new executive director of the Colorado Ovarian Cancer Alliance (COCA), effective December 1, 2013. She will succeed Guadalupe (Pep) Torres, who announced her resignation in September after serving as COCA's executive director since January 2011.

LifeSci Advisors Initiates Coverage of Sorrento Therapeutics
LifeSci Advisors, LLC

Prima BioMed Updates CVac Development Program; Clinical Trial Focus on Second-Remission Ovarian Cancer Patient Population
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"), in its most recent quarterly call, provided significant updates to its CVac™ clinical development program.

Prima BioMed and Neopharm Ltd Enter Into License for CVac in Israel

Phoenix Orthodontist to Participate in SPCA's Walk to Save Animals
For one Phoenix-area orthodontist, giving back to the community is one of the most significant hallmarks of his practice. Dr. Chris Murphy believes that the commitment to local outreach at Murphy Orthodontics is one of the things that distinguishes them as a unique orthodontic treatment center. Over the years, Dr

Prima BioMed First Quarter Report, Management Conference Call and CVac Program Update
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") yesterday released its Appendix 4C - Quarterly Report for the first quarter of financial year 2014, the three month period ending 30 September 2013.

New York Plastic Surgeons Hold Educational Summit Focused on Breast Reconstruction
Shortly after its inception, Long Island Plastic Surgical Group began directing a plastic surgery residency program as part of the organization's commitment to education -- a central component to the practice's philosophy

L2FU Searches for Missing Patients Bear Fruit in Clinical Trials
Long-term follow-up studies for specific medical conditions are essential. Such research studies are needed to critically evaluate the outcome of a treatment intervention However, in long-term studies it is easy for patients to stop participating and become 'lost-to-follow-up

Seragon Pharmaceuticals Raises $30M in Series A Financing
Seragon Pharmaceuticals Inc. today announced it has raised a total of $30 million in a Series A financing to advance the company's pipeline of therapies targeting hormone-driven cancers, including ARN-810 for the treatment of metastatic breast cancer. The financing included participation from venBio, Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group.

Glycotope Reported Promising First-in-Man Data of Novel Glycooptimized Monoclonal Anti-TA-MUC1 Antibody PankoMab-GEX(TM)
Glycotope GmbH /Glycotope Reported Promising First-in-Man Data of Novel Glycooptimized Monoclonal Anti-TA-MUC1 Antibody PankoMab-GEX(TM) . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Soricimed Shows Promise in Treating Breast and Ovarian Cancer
Soricimed Biopharma Inc

RayBiotech, Inc. Researchers Identify Biomarkers for Early Detection of Ovarian Cancer Using RayBio(R) Antibody Array Technology
RayBiotech, Inc. announced today that, in collaboration with scientists from several universities and institutes, the company's researchers have identified five biomarkers present in patient serum which allow for the early detection of ovarian cancer

Inspire Patient Engagement Community Reaches 400,000-Member Milestone
Inspire, the patient engagement platform, now has 400,000 members.

Prima BioMed Management Presentation of CVAC(TM) Phase 2 Trial Results
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") announced that management will deliver a presentation of the CAN-003 trial data via webcast and teleconference on Wednesday, October 2, 2013 at 8:00 a.m. (Sydney local time). This corresponds to Tuesday, October 1, 2013 at 6:00 p.m. U.S. Eastern daylight time.

Prima BioMed Releases Interim Immune Monitoring Data From CVac Clinical Trial
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") today released interim immune monitoring data from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy.

PropThink: Endocyte - A Safe Bet for 2013
By David SobekEndocyte (NASDAQ:ECYT) recently confirmed that the Marketing Authorization Application (MAA) filing process for vintafolide and etarfolatide in Europe is set to be completed by the end of 2012

Adelson Medical Research Foundation Funds International Collaborations in Cancer and Neurology
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private foundation funding collaborative translational science, announced today a new round of funding for global research programs in cancer and neurological disease. AMRF has just funded 13 collaborations involving 96 interacting projects

Blood Test With Potential to Detect Stage One Cancer: Soricimed Biopharma Inc. Announces Initiation of Cancer Diagnostic Study
Soricimed Biopharma Inc., a private clinical stage company developing novel cancer therapeutics and diagnostics, announced that a pre-regulatory study of their blood test for early detection of cancer has commenced.

What a Trip It's Been for Legendary Saxophonist Bill Trujillo, Who's Played With Frank, Dino, Elvis, Tony Bennett and Peggy Lee, and Now Takes Center Stage on 'Vegas,' a Jazz-Driven Homage to His Longtime Home Set for Release October 23
A fixture for several decades in the orchestras at such legendary hotels as the Tropicana, Sands, Stardust, Dunes, Frontier, Flamingo and MGM Grand, Los Angeles native Bill Trujillo has made Las Vegas his home for 50 years while backing everyone from Frank Sinatra and his Rat Pack pals Dean Martin and Sammy Davis, Jr. to Elvis, Ella Fitzgerald and Peggy Lee.

Positive Interim Data From CAN-003 Trial of CVac(TM) for Ovarian Cancer
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima"," the "Company") today announced positive trends in the interim data from the CAN-003 phase 2 clinical trial of CVac™ to treat epithelial ovarian cancer patients in remission after first-line or second line therapy. Dr

San Francisco Plastic Surgeon Participates in BRA Day
Dr. Karen Horton, a San Francisco Plastic Surgeon, says her role is "to educate, inform and empower women." Consequently, she is honored to host the San Francisco/Bay Area's National Breast Cancer Reconstruction Awareness Day (BRA Day) event, the only BRA Day event scheduled to take place in Northern California. October 17th will mark the first BRA Day celebrated in the United States.

Prima BioMed Releases Quarterly Shareholder Newsletter, Update on "CANVAS" Study Progress
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) ("Prima," the "Company") today released its quarterly Shareholder Newsletter available on the company website at http://primabiomed.com.au/investor/investor_update.php.

Update on NGR-hTNF Presented at ESMO Congress 2012
MolMed S.p.A. (MILAN: MLM) presented, at the 37th ESMO Congress, three studies on its investigational biological drug NGR-hTNF, including updated results in non-small cell lung cancer (NSCLC) patients and two retrospective analyses evaluating potential predictors of outcome in patients enrolled in Phase I and Phase II trials.

New Online Resource Gives Voice to the Advanced Breast Cancer Community Who Often Feels Overlooked, Especially During Breast Cancer Awareness Month
An online resource -- AdvancedBreastCancerCommunity.org -- relaunches just in time for Breast Cancer Awareness Month to help bring much-needed recognition to the advanced breast cancer community

Bavarian Nordic Reports Preliminary Data from Phase 2 Trial of CV-301 in Metastatic Breast Cancer
KVISTGAARD, Denmark, October 1, 2012 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary results from a randomized, open-label, multi-center Phase 2 study of CV-301 (CEA/MUC-1/TRICOM), an immunotherapy product candidate, in combination with docetaxel versus docetaxel alone for the treatment of metastatic breast cancer

Prima BioMed to Present at BIOX
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) announces that its CEO Matthew Lehman will present a corporate update at BIOX; Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus (USA) on September 24-25, 2012.

PropThink: Sunesis Increases Sample Size and Receives $25M in Conjunction
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) are rebounding from late losses on Monday, up 50% in premarket trading after the company announced an increase in the size of its lead phase 3 clinical trial, recommended by an independent Data and Safety Monitoring Board (DSMB). More importantly, however, the sample increase triggers a $25M investment from Royalty Pharma

Eisai Receives Orphan Drug Designation for Anticancer Agent Lenvatinib in Japan
Eisai Co., Ltd. announced today that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multikinase inhibitor lenvatinib mesylate ("lenvatinib") for the treatment of thyroid cancer, the drug's prospective indication

MolMed Board of Directors Approves the First Half-Year 2012 Financial Report
The Board of Directors of MolMed S.p.A. (MILAN: MLM), chaired by Professor Claudio Bordignon, today reviewed and approved the half-year financial report at 30 June 2012.

Healthcare review: Progenics & Salix Slump On FDA, pSivida & Vermillion Jump
U.S. stocks turned lower after posting three straight gains with the DOW trading down 15 points ahead of anticipated central-bank moves and the monthly jobs report later in the week. Several healthcare stocks are making notable news at mid day on Monday :- Vermillion, Inc. (NASDAQ:VRML) stock gained 5.56% to $1

Prima BioMed to Release Interim CVac Clinical Data
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim results from its CVac™ clinical trial CAN-003 in October 2012.

Protein Kinase Inhibitors, Monoclonal Antibodies & Vaccines Therapeutic Classes Dominate Late-Stage Oncology Pipeline
MarketResearch.com has announced the addition of the new report "Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline," to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/GBI-Research-v3759/Novel-Therapies-Oncology-Protein-Kinase-7061034/

Unprecedented progression-free survival benefit with afatinib* associated with clinically meaningful improvements in life-limiting lung cancer symptoms and better quality of life
For NON-US media only

Boehringer Ingelheim submits first oncology compound, afatinib* for European approval
For NON-US media only

Avastin delays ovarian cancer progression
A targeted drug therapy called bevacizumab (Avastin), when used in combination with existing treatments like chemotherapy delays progression of advanced ovarian cancer, a new study has suggested.

Tiny genetic variation can predict outcome of ovarian cancer treatment
A tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer, a new study has shown.

Common diabetes pill can cut risk of ovarian cancer by 40 pc
A drug widely used to treat patients with type two diabetes and that costs only 8p a day could be a major breakthrough in the prevention of ovarian cancer, according to a new study.

Gene behind breast cancer may also cause heart disease
An Indian origin surgeon has suggested that women who are at risk for breast cancer may also be at greater risk for heart disease.

Potential breakthrough in treating late-stage ovarian cancer
University of Guelph researchers have discovered a peptide that shrinks advanced tumours and improves survival rates for ovarian cancer.

'Muffin top' waistline puts women at risk of cancer and fuels its growth
Women with a bulging "muffin top" waistline are not only at greater risk of cancer, but their tumours are also likely to grow faster, according to a new study.

Ovarian cancer feeds on fat cells in abdomen
A research team based at the University of Chicago has found that large pad of fat cells that extends from the stomach and covers the intestines provides nutrients that promote the spread and growth of ovarian cancer.

New Year's Resolutions: eHealthInsurance Shows That Keeping Health-Related Goals May Save You Money
Today eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals, families and small businesses, described how keeping your New Year's resolutions and utilizing key health insurance benefits can help you save money.

MolMed Board of Directors Approves the Interim Financial Report at 30 September 2011
The Board of Directors of MolMed S.p.A. (MILAN: MLM), chaired by Professor Claudio Bordignon, today approved the interim financial report at 30 September 2011.

The Estée Lauder Companies Inc. Deeply Mourns the Death of Evelyn H. Lauder, Senior Corporate Vice President and Head of Fragrance Development Worldwide, and Founder of The Breast Cancer Research Foundation
The Estée Lauder Companies Inc. (ELC) announced the passing of Evelyn H. Lauder, Senior Corporate Vice President and Head of Fragrance Development Worldwide, at the age of 75 from complications of non-genetic ovarian cancer. Mrs. Lauder died on November 12, at her home in New York City with her family by her side.

Comment on this story

Share